Critical appraisal of guidelines for coronary artery disease on dual antiplatelet therapy: More consensus than controversies.

{"article_title":"Critical appraisal of guidelines for coronary artery disease on dual antiplatelet therapy: More consensus than controversies.","author":"Zhang, Shaozhao , Zhou, Huimin , Zhuang, Xiaodong , Yang, Daya , Sun, Xiuting , Zhong, Xiangbin , Lin, Xiaoyu , Hu, Xun , Huang, Yiquan , Liao, Xinxue , Du, Zhimin","journal_title":"Clinical cardiology","issn":"1932-8737 ; Electronic","isbn":"","publication_date":"20191201","volume":"42","issue":"12","first_page":"1170","page_count":"11","accession_number":"31609463","doi":"10.1002\/clc.23275","publisher":"John Wiley & Sons, Inc","doctype":"Journal Article; Review","subjects":"Clinical Cardiology","interest_area":["Cardiology"," Emergency Medicine"],"abstract":"Dual antiplatelet therapy (DAPT) in the form of aspirin plus a P <sub>2<\/sub> Y <sub>12<\/sub> inhibitor, when indicated, is one of the key treatments in coronary artery disease (CAD). Many recommendations on DAPT in patients with CAD based on current guidelines are largely inconsistent. In our current study, we aimed at systematically reviewing DAPT-relevant clinical practice guidelines, and highlighting their commonalities and differences for better informed decision-making.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=31609463&authtype=shib&custid=ns346513"}